Are Supplement Doses the Same Across Chews, Powders, Liquids, and Capsules?

By David Wilkes, DVM

✓ Medically reviewed by David Wilkes, DVM — August 6, 2026 For general education — not a substitute for veterinary care.

Comparisons · August 7, 2026 · 6 min read

The number on the label is a starting point, not a promise — the form it's delivered in changes what your dog actually absorbs.

A twelve-year-old Lab mix named Otis taught me this lesson more clearly than any textbook. His owner had switched him from a glucosamine powder she’d been sprinkling on his food for two years to a soft chew — same brand, same label dose, same “600 mg glucosamine” printed right on the front. Three weeks later she called, worried the new batch was “watered down,” because Otis’s stiffness after his morning walk seemed to be creeping back. Nothing about the ingredient had changed. What had changed was the form, and forms are not interchangeable the way owners assume.

Why the same milligram number doesn’t mean the same dose

Here’s the question at the center of this: if a chew, a powder, a liquid, and a capsule all list 600 mg of an ingredient, is your dog getting 600 mg of it? Not necessarily. The label tells you what went into the product. It doesn’t tell you what comes out the other side of digestion and actually reaches the bloodstream — and that gap is where a lot of supplement disappointment lives.

That gap has a name: bioavailability, the fraction of a dose that survives digestion and shows up where it can do something. A pharmacokinetics review of vitamin dosage forms found that formulation — not just the milligram count — meaningfully shifts how much of a nutrient the body actually uses, with liquids and powders generally dissolving and absorbing faster than solid forms that first have to break down (see the PMC: overview of vitamin dosage forms). A capsule shell or a dense chew matrix has to disintegrate before anything inside it is even available for absorption. A liquid or a fine powder skips that step.

Glucosamine and chondroitin, two of the most common joint-supplement ingredients for dogs, are a blunt illustration of how much this matters even before form is considered. A review of glucosamine and chondroitin use in canine osteoarthritis notes that oral glucosamine absorption runs around 12%, and chondroitin sulfate absorption is even lower, closer to 5% (see the PubMed: review on glucosamine and chondroitin use in canines). If that much of the dose is already lost to digestion in the best case, then the form delivering it — how fast it dissolves, whether it’s protected from stomach acid, whether it’s bound up in fillers — isn’t a minor detail. It’s a second variable stacked on top of an ingredient that was already inefficient to begin with.

What actually changes between chews, powders, liquids, and capsules

I want to be honest about where the science gets thin, because this is a topic that gets oversimplified in marketing copy. We don’t have head-to-head canine bioavailability data for every ingredient across every form — glucosamine in a chew versus the same milligram dose in a powder, tested in the same dogs, isn’t a study that exists for most products on the market. What we do have is general pharmacology: liquids and dissolved powders tend to be absorbed faster because there’s no shell or matrix to break down first; capsules add a disintegration step; dense chews, especially ones loaded with binders, oils, and palatants, can slow that further depending on how they’re formulated. Faster isn’t automatically better — a slower release can be exactly what’s wanted for some ingredients — but it does mean the form is doing real pharmacological work, not just serving as a delivery costume around an identical dose.

This is also why I tell owners not to assume a switch between forms is truly a lateral move, even when the front-of-label number stays the same. If you switch your dog from a capsule to a powder, or from a liquid to a chew, watch for a couple of weeks the way Otis’s owner did — stiffness after rest, willingness to take the stairs, how quickly they settle after a walk — rather than assuming the transition is invisible. It very often is invisible. But it isn’t guaranteed to be, and dogs with a genuinely borderline dose are the ones who reveal the difference first.

Quality control is the other half of this, and it’s where a credential like the Vetnique: National Animal Supplement Council actually earns its keep. NASC’s Quality Seal requires member companies to maintain documented quality control processes, submit to independent facility audits every two years, and back label claims with traceable, safety-verified ingredients tested by an outside lab. None of that guarantees identical bioavailability across a chew and a powder from the same company — that’s a formulation question the seal doesn’t answer. But it does mean the milligram figure on the label of a certified product is more likely to be the milligram figure actually in the product, which is the floor you need before form-related absorption differences are even worth worrying about. Our scoring rubric weighs exactly this: a verified dose you can trust, evaluated separately from how well that dose is likely to be absorbed in the form it’s sold in.

Where this actually shows up in practice

I’ve watched this play out most often with senior dogs on joint or cognitive support, because that’s where owners are most attentive to small changes and most likely to have switched forms for a practical reason — a dog who got harder to pill, an owner tired of measuring powder into wet food, a chew that suddenly wasn’t palatable anymore during an illness. One dog I worked with, a nine-year-old Golden Retriever with early hip changes, had been maintained for over a year on a joint powder mixed into her dinner. Her owner moved her to a chew for convenience during a stretch of frequent travel, and within about a month noted she was hesitating at the bottom porch step again, something that had resolved months earlier. We didn’t change anything else — same food, same activity level, same weather. The only variable was form. I can’t tell you that was the cause with certainty; dogs have good weeks and bad weeks for reasons that have nothing to do with supplements. But it was the variable that changed right before the symptom returned, and that timing is worth taking seriously rather than dismissing.

For a topic this size — longevity and cellular-health ingredients like NAD+ precursors are getting the same “which form matters” questions now that joint supplements have dealt with for years — the honest answer is that dosing form is one input among several, alongside ingredient identity, verified concentration, and how a product has actually been tested. Our longevity supplement verdict for senior dogs and our scored NAD+ supplement verdict both weigh form as part of the broader rubric rather than as the deciding factor on their own, because it usually isn’t.

The verdict

So: same milligrams, different dog experience? It’s possible, and for ingredients with already-thin absorption like glucosamine and chondroitin, it’s more than possible — it’s expected. Chews are convenient and generally well-tolerated, but their disintegration adds a step that powders and liquids skip. Capsules sit in between. None of this means chews are bad or powders are automatically superior; it means the label’s milligram count is the beginning of the evaluation, not the end of it, and a dog’s actual response over a few weeks tells you more than the front-of-package number ever will. If your dog is on a borderline dose for a real clinical reason, that’s a conversation for your veterinarian before you switch forms casually. If the switch is happening anyway, watching for the specific things that matter — gait, willingness to move, sleep, appetite — for two to three weeks is the closest thing to a controlled experiment most owners will ever run at home.

Is the science on form-specific bioavailability in dogs as settled as I’d like it to be? Honestly, no — and I’d rather say that plainly than pretend a tidy answer exists where the data hasn’t caught up yet.